Scientific article
OA Policy
English

A pharmaceutical policy accident: collision of shareholder capitalism and Chinese state capitalism driving the shortage of an essential antibiotic

Published inJournal of pharmaceutical policy and practice, vol. 17, no. 1, 2430441
Publication date2024
First online date2024-12-03
Abstract

Background: An explosion in a Chinese factory in 2016 caused a global shortage of essential broad-spectrum antibiotic piperacillin-tazobactam. Hitherto, no detailed, policy-relevant analysis has been conducted on this major shortage event. Thus, we aimed to (1) investigate causes; (2) describe supply chain challenges; and (3) uncover policy gaps to support possible mitigation actions.

Methods: Applying an analytical framework for security of medical supply chains, we investigated the changing roles of Pfizer-led and Chinese API suppliers. We identified demand surge, capacity reduction and co-ordination failures. Triangulating between scientific literature, corporate, and regulatory documents, we analysed the impact of Western and Chinese policy contexts on supply chain resilience.

Results: We uncovered 'red flags': geographically dispersed manufacturing failures due to complexity of sterile production; undetected supply chain concentration and interlinkages; and Chinese policy-led API supplier consolidation. We found these warning signals were ignored in the absence of a co-ordinated policy framework to identify and mitigate emerging global supply risks. Firstly, policy makers lacked visibility on growing 'volume dependency' in the chain. Secondly, national policy makers lacked a global view of supply risk. Thirdly, we show antibiotic API manufacturing economics were impacted by a number of non-pharmaceutical policy decisions (e.g. state aid, environmental standards, procurement rules) which contributed to supply chain vulnerability.

Conclusions: Our findings suggest possible policy gaps in governance of supply chain resilience. Firstly, disclosure of API suppliers including degree of dependency may better pre-empt bottlenecks, facilitating priority setting for public investments in re-shoring where global API supply currently relies on few, or single plants; secondly, a whole-of-government approach may counter the potential impact of non-pharmaceutical policies on supply chain resilience. Our findings confirm suggestions from previous studies that international data sharing would be beneficial considering the global shortage effects which can emerge from a single point of failure.

Keywords
  • AMR
  • API
  • Antibiotic shortages
  • China
  • Pfizer
  • Capitalism
  • Global health security
  • Pharmaceutical policy
  • Piperacillin-tazobactam
  • Resilience
  • Supply chain
Citation (ISO format)
WELLS, Nadya Christina, NGUYEN, Vinh-Kim, HARBARTH, Stéphan Juergen. A pharmaceutical policy accident: collision of shareholder capitalism and Chinese state capitalism driving the shortage of an essential antibiotic. In: Journal of pharmaceutical policy and practice, 2024, vol. 17, n° 1, p. 2430441. doi: 10.1080/20523211.2024.2430441
Main files (1)
Article (Published version)
Identifiers
Journal ISSN2052-3211
64views
422downloads

Technical informations

Creation18/12/2024 09:55:49
First validation13/02/2025 08:10:59
Update13/02/2025 08:10:59
Status update13/02/2025 08:10:59
Last indexation13/02/2025 08:11:00
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack